Wei L, et al. - Given that combination treatment with sofosbuvir and velpatasvir has resulted in high sustained virological response rates in patients chronically infected with hepatitis C virus (HCV) with genotypes 1–6 in clinical trials and real-world settings, researchers evaluated its efficacy and safety in Asia, a region with diverse HCV genotypes. Between April 14, 2016, and June 30, 2017, 375 patients were admitted to the study; 374 completed the full course of treatment and 1 stopped treatment. It was concluded that single-tablet sofosbuvir-velpatasvir for 12 weeks is an effective and safe treatment for patients with chronic HCV infection in this study population but may be less effective for those infected with HCV genotype 3b and cirrhosis. Upper respiratory tract infection and headache were the most common adverse events.